HBx biofarm in pilot scale. © HutanBio

British-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water.

©Pixabay.com

After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.
 

       

Corporate headquarters of Jazz Pharmaceuticals are located in Dublin, Ireland. © Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.

Heura co-founders Marc Coloma (left) and Bernat Ananos Martinez (right). © Heura

Spanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.

3PBiovian that has an office in Boston will produce at Biovian's site in Turku, Finland, and 3 Bio's manufacturing site in Pamplona, Spain. © 3PBIOVIAN

Biovian and 3P Biopharmaceuticals have created a new pan-European CDMO, dubbed 3PBIOVIAN.

Picture: OCI

Stefanos Theoharis joins OneChain Immunotherapeutics (OCI) as new CEO. He follows Jorge Alemany, CEO since 2022, when the Spin-off from the Josep Carreras Leukemia Research Institute has started.

Veeva_ad.jpeg

Despite individual regulatory bodies having their own unique set of requirements, for most organisations, the challenges associated with annual product quality reviews (APQR) are largely the same. Issues with fragmented systems and paper-based processes prove increasingly burdensome.

© MikeMareen

To improve mRNA product analysis, the Lonza Group Ltd. and Oxford Nanopore Technologies plc. are working together to develop and market a test to assess multiple critical quality attributes of mRNA products

Picture: DesignLabSquare

Dr Rob Scott, former Chief Medical Officer and Head of Development at AbbVie, joined Abionyx Pharma in January as new CMO and Head of Research and Development.

© magicmine - stock.adobe.com

Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.